Reflux esophagitis is a condition in which gastroesophageal reflux causes breakage of the esophageal mucosa and is accompanied by symptoms such as acid reflux and heartburn. According to the mechanism of the pathogenesis of reflux esophagitis, the principle of its treatment is to enhance the anti-reflux defense mechanism, reduce the stimulation of reflux and strengthen the resistance of esophageal mucosa, so as to relieve the symptoms, cure the disease and prevent recurrence. Treatment includes the following: i. General treatment Also known as lifestyle changes, is part of the treatment of reflux esophagitis. Common recommendations include: reducing body weight, elevating the head of the bed, quitting smoking and alcohol, avoiding eating before bedtime, not lying in bed after meals, and avoiding foods that may trigger reflux symptoms, such as coffee, chocolate, spicy or acidic foods, and high-fat diets. The first thing you need to do is to take a look at the actual website. Since 80% of reflux esophagitis reoccurs after 6 months of drug withdrawal, maintenance therapy is required, including on-demand and long-term treatment. On-demand therapy can be used for patients with mild disease, while patients with severe disease need long term maintenance therapy. Prokinetic drugs: e.g., mosapride, domperidone. These drugs have some anti-reflux effect, but poor efficacy when applied alone. Gastric mucosa protective agents: such as magnesium aluminum carbonate, bismuth, etc. Can enhance the resistance of the esophageal mucosa, conducive to the relief of symptoms, but almost no effect on mucosal healing. But magnesium aluminum carbonate has the effect of adsorbing bile. Third, surgical treatment endoscopic treatment: the methods are radiofrequency, local injection and endoscopic suturing 3. Long-term efficacy and complications are subject to further follow-up observation. Surgical treatment: Failure of proton pump inhibitor therapy is one of the indications for anti-reflux surgery, and laparoscopic fundoplication is a commonly used procedure with good surgical results for patients with abnormal esophageal acid exposure. In patients with extraesophageal symptoms who have failed PPI therapy, the efficacy of surgery is not known and surgical treatment is not recommended at this time. Most reflux esophagitis is chronic and recurrent, with relapse after discontinuation of treatment, and the long-term course of the disease has a greater impact on the patient’s quality of life. With continuous improvement in treatment and intensive research, the cure rate of reflux esophagitis is gradually increasing and the incidence of serious complications tends to decrease.